carvedilol has been researched along with Metabolic Syndrome in 6 studies
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of the present study was to explore the effect of carvedilol treatment on metabolic parameters in patients with metabolic syndrome." | 9.12 | The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. ( Oguz, A; Uzunlulu, M; Yorulmaz, E, 2006) |
| "We tested the hypothesis that long-term caffeine intake prevents the development of insulin resistance and hypertension in two pathological animal models: the high-fat (HF) and the high-sucrose (HSu) diet rat." | 7.78 | Chronic caffeine intake decreases circulating catecholamines and prevents diet-induced insulin resistance and hypertension in rats. ( Conde, SV; Gonzalez, C; Guarino, MP; Monteiro, EC; Mota Carmo, M; Nunes da Silva, T, 2012) |
| "In an open prospective 16-week study we carried out assessment of clinical efficacy, vaso- and cardioprotective properties of nonselective alpha and beta-adrenoblocker carvedilol used as monotherapy and in combination with nifedipine or as combination of these drugs with metformin and simvastatin." | 6.74 | [Provision of complex cardioprotection with the help of carvedilol in 1-2 degree arterial hypertension combined with metabolic syndrome]. ( Eliseeva, IV; Gusakovskaia, LI; Matrosova, IB; Oleĭnikov, VE; Tomashevskaia, IuA, 2009) |
| "The objective of the present study was to explore the effect of carvedilol treatment on metabolic parameters in patients with metabolic syndrome." | 5.12 | The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. ( Oguz, A; Uzunlulu, M; Yorulmaz, E, 2006) |
| "We tested the hypothesis that long-term caffeine intake prevents the development of insulin resistance and hypertension in two pathological animal models: the high-fat (HF) and the high-sucrose (HSu) diet rat." | 3.78 | Chronic caffeine intake decreases circulating catecholamines and prevents diet-induced insulin resistance and hypertension in rats. ( Conde, SV; Gonzalez, C; Guarino, MP; Monteiro, EC; Mota Carmo, M; Nunes da Silva, T, 2012) |
| "In an open prospective 16-week study we carried out assessment of clinical efficacy, vaso- and cardioprotective properties of nonselective alpha and beta-adrenoblocker carvedilol used as monotherapy and in combination with nifedipine or as combination of these drugs with metformin and simvastatin." | 2.74 | [Provision of complex cardioprotection with the help of carvedilol in 1-2 degree arterial hypertension combined with metabolic syndrome]. ( Eliseeva, IV; Gusakovskaia, LI; Matrosova, IB; Oleĭnikov, VE; Tomashevskaia, IuA, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Riabykina, GV | 1 |
| Chazova, IE | 1 |
| Mychka, VB | 1 |
| Shutova, LI | 1 |
| Shishova, TV | 1 |
| Liutikova, LN | 1 |
| Kozhemiakina, ESh | 1 |
| Shchedrina, EV | 1 |
| Sobolev, AV | 1 |
| Oleĭnikov, VE | 1 |
| Matrosova, IB | 1 |
| Eliseeva, IV | 1 |
| Tomashevskaia, IuA | 1 |
| Gusakovskaia, LI | 1 |
| Carella, AM | 1 |
| Antonucci, G | 1 |
| Conte, M | 1 |
| Di Pumpo, M | 1 |
| Giancola, A | 1 |
| Antonucci, E | 1 |
| Conde, SV | 1 |
| Nunes da Silva, T | 1 |
| Gonzalez, C | 1 |
| Mota Carmo, M | 1 |
| Monteiro, EC | 1 |
| Guarino, MP | 1 |
| Uzunlulu, M | 1 |
| Oguz, A | 1 |
| Yorulmaz, E | 1 |
| Fardoun, RZ | 1 |
2 reviews available for carvedilol and Metabolic Syndrome
| Article | Year |
|---|---|
Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Carbazoles; Carvedilol; Ethanolam | 2010 |
Carvedilol versus cardioselective beta-blockers for the treatment of hypertension in patients with type 2 diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Diabetes Mellitus, Typ | 2006 |
2 trials available for carvedilol and Metabolic Syndrome
| Article | Year |
|---|---|
[Provision of complex cardioprotection with the help of carvedilol in 1-2 degree arterial hypertension combined with metabolic syndrome].
Topics: Adrenergic alpha-Antagonists; Adult; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Femal | 2009 |
The effect of carvedilol on metabolic parameters in patients with metabolic syndrome.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anthropometry; Antihypertensive Ag | 2006 |
2 other studies available for carvedilol and Metabolic Syndrome
| Article | Year |
|---|---|
[Heart rate variability dynamics during treatment of arterial hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Benzopyrans; Blood Pressure; Carb | 2008 |
Chronic caffeine intake decreases circulating catecholamines and prevents diet-induced insulin resistance and hypertension in rats.
Topics: Adiposity; Adrenergic Antagonists; Animals; Body Weight; Caffeine; Carbazoles; Carvedilol; Catechola | 2012 |